← Back

GeneDx: GeneDx Holdings Corp. Delivers Strong Q4 2025 Results

GeneDx Holdings Corp. reported quarterly revenues of $121 million, bringing full-year revenues to $428 million, driven by 54% exome and genome revenue growth. The company's adjusted gross margin was 71% for the fourth quarter and full year 2025. The actual EPS came out at '-0.65694' relative to estimates at '0.11'. The company's financial performance was highlighted by a 27% year-over-year increase in total revenues, with exome and genome revenues growing 32%. GeneDx reported 27,761 exome and genome test results in the fourth quarter, with a consistent trend of acceleration throughout the year.

WGS

USD 80.7

-7.33%

A-Score: 3.4/10

Publication date: February 23, 2026

Full Report

Author: Analystock.ai

📋 Highlights
  • Revenue Growth: Full-year 2025 revenues reached $428M, up 27% YoY, driven by 54% exome/genome revenue growth and 27,761 tests in Q4.
  • 2026 Guidance: Revenue forecast of $540–$555M, with 33–35% exome/genome volume growth and 33% Q1 baseline growth, led by NICU and prenatal markets.
  • Margin Stability: Adjusted gross margin of 71% in Q4 2025, targeting 70% in 2026, with positive adjusted net income expected year-round.
  • Market Expansion: 50-person sales team targeting general pediatrics (18–24-month adoption curve) and 5% NICU penetration in Q4, with plans to scale reps in 2027.

Guidance and Growth Expectations

The company is reaffirming its guidance to include total revenues in the range of $540 to $555 million, exome and genome volume growth of 33% to 35%, and a baseline of 33% growth for Q1. The foundational markets are expected to contribute 25% to 27% towards the growth rate, while expansion markets are expected to contribute 7% to 8%. Adjusted gross margin is expected to be approximately 70%, and adjusted net income is expected to be positive for the full year and each individual quarter. As Katherine Stueland mentioned, "GeneDx Infinity enables fast and accurate diagnoses at scale, and the company has a strong and fast-growing core."

Valuation Metrics

Analysts estimate next year's revenue growth at 23.7%. The current valuation metrics indicate a 'P/S Ratio' of 5.89, 'P/E Ratio' of -111.4, 'P/B Ratio' of 7.6, and 'EV/EBITDA' of -189.07. These metrics suggest that the market is pricing in significant growth expectations for GeneDx Holdings Corp.

Growth Drivers

The company's growth drivers in 2026 include pediatric neurology, prenatal, and NICU, with NICU expected to be the largest contributor. GeneDx is taking a conservative view on gross margins, aiming to optimize cost and reimbursement for its exome and genome portfolio. The company is also investing in its commercial footprint, customer experience, and R&D to support clinical research and commercial strategy.

Expansion and Competition

GeneDx is expanding its dedicated sales team and leveraging AI to enhance diagnostic capabilities. The company is confident in its competitive moat and is investing in R&D to maintain its position amidst new entrants in the market. As the company continues to grow, it is well-positioned to capitalize on the momentum driven by its advanced technology and capabilities.

GeneDx's A-Score